Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07104565 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
A Phase 2 study of Immune Thrombocytopenia, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 20
- Study locations
NCT07104565 is a Phase 2 study of Immune Thrombocytopenia that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 56 participants, below the 114-participant average among 6 other Immune Thrombocytopenia trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT07104565, a Phase 2 study of Immune Thrombocytopenia, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
Conditions Studied
Interventions
- DRUG INCA000585
Study Locations (20)
Other
- Chu Angers - Hôpital Hôtel Dieu - Angers
- Chu Caen - Hôpital de La Côte de Nacre - Caen
- Hôpital Henri Mondor - Créteil
- Chu Dijon - Hopital Du Bocage - Dijon
Victoria
- Box Hill Hospital - Box Hill
- Monash Medical Centre Clayton - Clayton
- The Alfred Hospital - Melbourne
Queensland
- Townsville University Hospital - Douglas
- Princess Alexandra Hospital Australia - Woolloongabba
Arizona
- Palo Verde Cancer Specialists Palo Verde Hematology Oncology, Ltd Glendale - Glendale
California
- Usc Norris Comprehensive Cancer Center - Los Angeles
Colorado
- Rocky Mountain Cancer Centers - Lone Tree
Connecticut
- Yale University School of Medicine - New Haven
Florida
- Gnp Research - Cooper City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-12-29 |
| Est. Completion | 2028-03-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07104565
The ClinicalTrials.gov registry entry for NCT07104565 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 114-participant average among 6 other Immune Thrombocytopenia trials with a reported enrollment target (51% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Immune Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which INCA000585 is the first listed.
NCT07104565 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Victoria, Queensland.
Frequently Asked Questions
What is clinical trial NCT07104565 about?
NCT07104565 is a clinical study titled "Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders". This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
What is the current status of trial NCT07104565?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2025-12-29. Estimated completion is 2028-03-09.
What conditions does trial NCT07104565 study?
This clinical trial studies the following conditions: Immune Thrombocytopenia.
What interventions are being tested in trial NCT07104565?
The interventions under investigation include: INCA000585 (DRUG).
Who is sponsoring clinical trial NCT07104565?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07104565 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
RECRUITING
-
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
RECRUITING · Phase 3
-
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
COMPLETED · Phase 4
-
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.